nach oben

Erschienen in:

01.06.2009 | Original Article

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience

verfasst von: Angelo Ghezzi, Maria Pia Amato, Pietro Annovazzi, Marco Capobianco, Paolo Gallo, Loredana La Mantia, Maria Giovanna Marrosu, Vittorio Martinelli, Nicoletta Milani, Lucia Moiola, Francesco Patti, Carlo Pozzilli, Maria Trojano, Mauro Zaffaroni, Giancarlo Comi, The ITEMS (Immunomodulatory Treatment of Early-onset MS) Group

Erschienen in: Neurological Sciences | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

The main objective of this study is to evaluate the effect of immunomodulatory agents (IMAs) (Interferon-Beta, Glatiramer Acetate) in a large cohort of multiple sclerosis (MS) patients with disease onset in childhood or adolescence, treated before 16 years of age, after a long-term follow-up. A total of 130 patients were identified, 77 were treated with Avonex, 39 with Rebif/Betaferon, 14 with Copaxone. After a mean (SD) treatment duration of 53.6 ± 27.0, 59.9 ± 39.5 and 74.6 ± 35.5 months, respectively, the relapse rate decreased significantly. The final EDSS score was unchanged with respect to the initial score. Similar results were also observed in subjects who continued a long-term follow-up after they were included in an observational study in 2004, and in subjects who were treated before 12 years of age. The frequency of clinical and laboratory adverse events was similar to that observed in adult patients. To conclude, IMAs were effective and well tolerated in paediatric patients with MS.

Nur mit Berechtigung zugänglich

Goodin DS, Frohman EM, Garmany GP et al, the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178

Waubant E, Hietpas J, Stewart T et al (2001) Interferon-beta1a in children with multiple sclerosis is well tolerated. Neuropediatrics 32:211–213PubMedCrossRef

Mikaeloff Y, Moreau T, Debouverie M et al (2001) Interferon-beta treatment in patients with childhood onset multiple sclerosis. J Pediatr 139:443–446PubMedCrossRef

Pohl D, Rostasy K, Gartner J, Hanefeld F (2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 64:888–890PubMed

Banwell B, Reder AT, Krupp L et al (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66:472–476PubMedCrossRef

Tenembaum SN, Segura MJ (2006) Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 67:511–513PubMedCrossRef

Ghezzi A, Amato MP, Capobianco M et al, the Immunomodulatory Treatment of Early Onset MS Group (2005) Disease modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 11:420–424

Pakdaman H, Fallah A, Sahraian MA et al (2006) Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics 37:257–260PubMedCrossRef

Ghezzi A, on behalf of the Immunomodulatory Treatment of Early Onset MS ITEMS Group (2005) Immunomodulatory treatment of early onset MS: results of an Italian co-operative study. Neurol Sci 26(suppl 4):S183–S186PubMedCrossRef

10.

Ghezzi A, Amato MP, Capobianco M et al (2007) Treatment of early-onset multiple sclerosis with intramuscular Interferon-beta1a: long term results. Neurol Sci 28:129–134CrossRef

11.

McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121–127PubMedCrossRef

12.

Lublin F, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911PubMed

13.

Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMed

14.

Mikaeloff Y, Caridare G, Tardieu M et al (2008) Effectiveness of early interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol 12:205–209PubMedCrossRef

15.

Kornek B, Bernert G, Balassy C et al (2003) Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 34:120–126PubMedCrossRef

16.

Ghezzi A, Pozzilli C, Liguori M et al (2002) Prospective study of multiple sclerosis with early onset. Mult Scler 8:115–118PubMedCrossRef

17.

Gusev E, Boiko A, Bikova O et al (2002) The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 104:203–207PubMedCrossRef

18.

Renoux C, Vukusic S, Mikaeloff Y et al (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356:2603–2613PubMedCrossRef

19.

Banwell B, Krupp L, Kennedy J et al (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6:773–781PubMedCrossRef

20.

Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66:54–59PubMedCrossRef

Titel: Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience
verfasst von: Angelo Ghezzi
Maria Pia Amato
Pietro Annovazzi
Marco Capobianco
Paolo Gallo
Loredana La Mantia
Maria Giovanna Marrosu
Vittorio Martinelli
Nicoletta Milani
Lucia Moiola
Francesco Patti
Carlo Pozzilli
Maria Trojano
Mauro Zaffaroni
Giancarlo Comi
The ITEMS (Immunomodulatory Treatment of Early-onset MS) Group
Publikationsdatum: 01.06.2009
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe 3/2009
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-009-0083-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Decreased bilateral cortical representation patterns in writer’s cramp: a functional magnetic resonance imaging study at 3.0 T

Course and outcome of a voltage-gated potassium channel antibody negative Morvan’s syndrome

The combination of vitamin D3 and dehydroascorbic acid administration attenuates brain damage in focal ischemia

TNF-related apoptosis-inducing ligand level in Alzheimer’s disease

Peroneal nerve orthodromic sensory conduction technique: normative data

Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie